HOME ZACKS RESEARCH FUNDS PORTFOLIO BROKER RESEARCH MARKETS SCREENING VIDEO EDUCATION SERVICES
Earnings    EPS Surprises    Mutual Funds    Options            My Account    Help    
Quote:
Login Free Membership
Search:

RELATED LINKS
Free Membership
Premium Home
Zacks #1 Rank
Real Time Insight
Equity Research
My Portfolio
Stock Screener
Premium Screens
Mutual Funds
ETFs
RSS Feed
Profit from the Pros
Subscription Services
FTM Trader
Product Guide
Zacks Premium
Method for Trading
Chart Patterns Trader
Home Run Investor
Income Plus
Insider Trader
Options Trader
Reitmeister Trader
Reitmeister Value
Tactical Trader
Top 10 Stocks
Turnaround Trader
Whisper Trader
Research Wizard
Zacks Ultimate



Zacks Premium
Get profitable stock
picks and timely
market advice in
Zacks.com`s Free
Daily Newsletter!

Free Registration

View the Archive


ACOR: ACORDA THERAPEUTICS INC - Stock Quote Enter Ticker:
 

QuoteEstimatesCharts Company ReportsNewsFinancials
  Quote |  Detailed Quotes |  Real Time |  Options Chain |  Greeks Montage

ACORDA THERAPEUTICS INC (NASD)
ACOR 22.54 -0.12 (-0.53%) Vol.  233,105 16:00 ET

Zacks Rank: 3 - Hold

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.
Zacks Rank Definition Annualized Return
# 1Strong Buy26.04%
# 2Buy18.27%
# 3Hold9.49%
# 4Sell3.94%
# 5Strong Sell1.6%
S&P5009.23%
Zacks Rank Education - Learn more about the Zacks Rank
Zacks Rank Home - All Zacks Rank resources in one place
Zacks Premium - The only way to get access to the Zacks Rank


Day Low - High 22.32 - 22.68
52wk Low - High 18.36 - 33.48
Avg Volume 422,293
Industry MED-BIOMED/GENE
Market Cap 899.63 M
Div - Yield 0.00 - 0.00
PE (forward) 37.61
PEG Ratio 1.34
Current Year Est. .6
EPS Last Year 1.43
Detailed Quote


Premium Research: Stock Analysis

Zacks Rank

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.
Zacks Rank Definition Annualized Return
# 1Strong Buy26.04%
# 2Buy18.27%
# 3Hold9.49%
# 4Sell3.94%
# 5Strong Sell1.6%
S&P5009.23%
Zacks Rank Education - Learn more about the Zacks Rank
Zacks Rank Home - All Zacks Rank resources in one place
Zacks Premium - The only way to get access to the Zacks Rank


Short-Term Rating 1-3 Months
Zacks #1 Rank Strong Buys Zacks Premium
down 3 - Hold
Zacks Recommendation

Zacks Recommendations are an excellent predictor of stock price movement over a 6+ month time frame. The recommendations come from the Zacks Equity Research group which combines the Zacks Rank with the insights from their team of over 50 equity analysts. The result is superior long term stock ratings.

The Zacks Recommendations are split into 3 groups: Outperform, Neutral and Underperform. When Zacks Premium members click on the recommendation it will launch them to the Zacks Equity Research report for the stock. More on these reports below.

Difference Between Zacks Rank and Zacks Recommendation
Zacks Equity Research Home
Zacks Premium - The only way to get access to Zacks Recommendations


Long-Term Rating 6+ Months
All Outperform Rated Stocks Zacks Premium
PREMIUM
Zacks Industry Rank

Which industries are set to outperform or underperform the market? You'll find the answer here. We have broken down all industries into over 200 classifications. Then ranked these industries using the most powerful indicator we know (the Zacks Rank). The higher the industry rank, the better the industry should perform in the future. Once you have found an attractive industry then check out the Rank in Industry to find the best stocks within the industry.

When Zacks Premium members click on the Zacks Industry Rank link they will see the full listing of industries and their current rankings.

About Zacks Industry Rank
Zacks Industry Rank - All current industry ranks.
Zacks Premium - The only way to get access to the Zacks Industry Rank

PREMIUM
Target Price

The Zacks Price Target provides you our expectation for a stocks share price in the next 6 months. These price targets are created by the Zacks Equity Research group to coincide with their recommendations that are also based on a 6 month time horizon.

Zacks Equity Research Home
Zacks Premium - The only way to get access to the Zacks Price Targets

PREMIUM
Equity Research Report

The Zacks Recommendations and Zacks Target Prices are just two of the valuable resources you'll find in the reports created by the Zacks Equity Research group. When Zacks Premium members click on this link they will taken to a page that gives them access to the Zacks Equity Research report for the stock.

Zacks Equity Research Home Zacks Premium - The only way to get access to Zacks Recommendations


Updated as of 05/16/2012
PREMIUM
Get all our stock ratings and recommendations with a Free Trial to Zacks Premium

Premium Research: Industry Analysis

Top Peers Ticker Zacks Rank
ACORDA THERAPEUTICS INC ACOR 3
AFFYMAX INC AFFY 1
AGENUS INC AGEN 1
HESKA CORP HSKA 1
Top Peer Analysis Zacks Premium
See all MED-BIOMED/GENE Peers

BROKERAGE RECOMMENDATIONS
Current ABR 2.44
ABR (Last Week) 2.44
# of Recs in ABR 9
Average Target Price 29.00
Rank in Industry 142 out of 176
More Brokerage Recommendations


NYSE data is at least 20 minutes delayed.
NASDAQ data is at least 15 minutes delayed.

 Interactive Java Charting
 NEW!   Fundamental Charts




Zacks Community PeopleAndPicks.com
Community Rating

PeopleAndPicks.com Community Stock Ratings

Rating Recommendation % of Stocks
5 stars Strong Buy 10%
4 stars Buy 20%
3 stars Hold 40%
2 stars Sell 20%
1 stars Strong Sell 10%
0 stars Not Rated  

We believe that a community of investors working together can create a superior stock rating system. Some call this "collective intelligence". Or simply...together we can beat the market!

A stock's Community Rating is calculated based on the aggregate input of the PeopleAndPicks Community. The proportion of buy to sell ratings, recency of analysis, and the average score of the users who rate it favorably all factor into a score of one to five stars.


How do you rate ACOR?

Buy Sell
Find out what the Zacks Community
thinks of ACOR at PeopleAndPicks.com
 
ZACKS COMMENTARY FOR ACOR
Zacks Equity Research: Report for ACOR
May 16, 2012
Zacks Blog: Revenues Climb at Acorda
May 04, 2012
Zacks Blog: Zacks #1 Rank Additions for Tuesday
Apr 17, 2012
Zacks Blog: Biogen's Fampyra Launched in Canada
Apr 13, 2012
Zacks Blog: Earnings Beat for Acorda
Feb 21, 2012
Zacks Blog: Ampyra Drives Acorda Revenues
Nov 09, 2011
Zacks Blog: Company News for October 6, 2011
Oct 06, 2011
Zacks Blog: Unfavorable Ruling for Acorda
Sep 12, 2011
More Zacks Commentary
NEWS
Acorda Therapeutics (ACOR) Could Fall Through $21.28 Support Level - Story Title - Comtex
May 22, 2012
Acorda Therapeutics Earnings Review: 18 Days after Announcement Shares Down 9.7% (ACOR) - Story Title - Comtex
May 21, 2012
Arqule has Relatively Underperformed its Peers in the Biotechnology Industry (ARQL, ITMN, IDIX, ACOR, REGN) - Story Title - Comtex
May 21, 2012
Acorda Therapeutics Earnings In Retrospect: Down 9.7% in the Last 16 Days (ACOR) - Story Title - Comtex
May 19, 2012
Acorda Therapeutics Shares Sinking Lower, Down 7.4% - Story Title - Comtex
May 18, 2012
Health Care Sector Wrap - FOXBusiness.com
May 18, 2012
Shares of Acorda Therapeutics Are Moving Lower on 1.2x Above-Average Volume (ACOR) - Story Title - Comtex
May 18, 2012
UPDATE: Goldman Sachs Initiates Sell on Acorda Therapeutics; Ampyra Risk - Benzinga
May 18, 2012
More News
EARNINGS ESTIMATES
  This Quarter
06/2012
Next Quarter
09/2012
This Year
12/2012
Next Year
12/2013
Average Estimate 0.13 0.13 0.60 0.99
Number of Estimates 9 9 8 10
Low Estimates 0.01 0.06 0.46 0.79
High Estimate 0.23 0.18 0.72 1.45
Year Ago EPS 0.07 0.85 1.23 0.60
EPS Growth 87.30% -84.97% -51.02% 63.82%

More Estimates

COMPANY DESCRIPTION
Acorda Therapeutics is commercial-stage biopharmaceutical company dedicated to the identification, development and commercialization of novel therapies that improve neurological function in people with multiple sclerosis, spinal cord injury and other disorders of the central nervous system. Acorda currently markets Zanaflex Capsules for the management of spasticity. The Company's lead product candidate, Fampridine-SR, for the improvement of walking ability in persons with multiple sclerosis. It develops therapies that restore neurological function to people with spinal cord injury, multiple sclerosis and related conditions of the nervous system.

Full Company Report
FINANCIALS
EPS TTM 1.43
Sales 292.24
Net Income 39.12
Price/Earnings 15.85
Price/Book 4.11
Price/Cash Flow 14.84
Price/Sales 2.98


More Financials

 
About Zacks | Advertise | Affiliate | Media | Careers | Contact Us | Help
Disclaimer | Privacy Policy | Sitemap
NYSE and AMEX data is at least 20 minutes delayed.  NASDAQ data is at least 15 minutes delayed.
Copyright 2012 Zacks Investment Research